ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
The fund remains heavily tilted toward large-cap pharma leaders like Sun, Cipla, and Dr. Reddy's, with the top five commanding nearly 40 percent—typical of a thematic play betting on India's pharmaceutical export dominance and domestic consumption growth. The manager's recent moves—exiting Treasury bills, adding Abbott for healthcare services diversification, and trimming Aurobindo while boosting Cohance—suggest conviction in specialty and CDMO players over commodity generics, reflecting confidence in margin expansion and value-addition opportunities in the sector.
Portfolio analysis · April 2026
NAV & Returns
| Plan | NAV | 1M | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Primary | ₹24.3700 | +8.55% | +0.99% | +17.85% | +6.39% |
Portfolio Metrics(latest month)
vs Category Peers
Highly DifferentiatedActive Share = ½Σ|wfund − wpeer|, computed using leave-one-out peer portfolio within SEBI category.
Similar Funds in Category
What Changed2026-03-31 → 2026-04-30
| Stock | Weight |
|---|---|
| Abbott India Ltd. | 1.88% |
Full Holdings
| # | Holding | % to NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Ltd. INE044A01036 | 11.76% |
| 2 | Cipla Ltd. INE059A01026 | 8.15% |
| 3 | Mankind Pharma Ltd. INE634S01028 | 7.58% |
| 4 | Divi's Laboratories Ltd. INE361B01024 | 6.06% |
| 5 | Dr. Reddy's Laboratories Ltd. INE089A01031 | 5.94% |
| 6 | Biocon Ltd. INE376G01013 | 5.81% |
| 7 | Cohance Lifesciences Ltd. INE03QK01018 | 4.44% |
| 8 | Lupin Ltd. INE326A01037 | 3.80% |
| 9 | Medplus Health Services Ltd INE804L01022 | 3.37% |
| 10 | Alkem Laboratories Ltd. INE540L01014 | 3.24% |
| 11 | Syngene International Ltd. INE398R01022 | 3.09% |
| 12 | TREPS | 2.19% |
| 13 | Akums Drugs and Pharmaceuticals Ltd. INE09XN01023 | 2.02% |
| 14 | Pfizer Ltd. INE182A01018 | 1.96% |
| 15 | Aurobindo Pharma Ltd. INE406A01037 | 1.93% |
| 16 | Abbott India Ltd. INE358A01014 | 1.88% |
| 17 | Thyrocare Technologies Ltd. INE594H01019 | 1.88% |
| 18 | J.B.Chemicals & Pharmaceuticals Ltd. INE572A01036 | 1.77% |
| 19 | Alembic Pharmaceuticals Ltd. INE901L01018 | 1.74% |
| 20 | Alivus Life Sciences Ltd. INE03Q201024 | 1.72% |
Sector Allocation
Top 10 sectors by % to NAV. Excludes derivatives.
Frequently Asked Questions
How many stocks does ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund hold?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund holds 38 stocks as per the latest AMFI portfolio disclosure. The top 5 positions account for 39.50% of NAV.
What is the largest holding in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
The largest position in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is Sun Pharmaceutical Industries Ltd., accounting for 11.76% of NAV in the Pharmaceuticals & Biotechnology sector.
Is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund a concentrated or diversified fund?
With a Gini coefficient of 0.469, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is moderately concentrated. The HHI concentration index is 48,288 bps, which is above the 2500 bps threshold for high concentration. The top 5 holdings together make up 39.50% of the portfolio.
What is the market cap allocation of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
Based on SEBI's AMFI classification, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund's equity portfolio is split as: Large Cap: 31.92%, Mid Cap: 26.51%, Small Cap: 38.32%. This reflects the fund's positioning within the market cap spectrum.
Which sectors does ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund invest in most?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund has the highest allocation to Pharmaceuticals & Biotechnology (81.92%), Healthcare Services (6.69%), Retailing (5.09%). The fund is invested across 6 sectors in total.
How actively managed is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund compared to other Sectoral / Thematic funds?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund has an Active Share of 91.36%, classifying it as "Highly Differentiated" among 237 Sectoral / Thematic peers. This means the fund takes significantly different stock positions compared to its category peers.
What changed in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund's portfolio in the latest month?
Between 2026-03-31 and 2026-04-30, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund added 1 new stock (including Abbott India Ltd.) and exited 2 stocks (including Glenmark Pharmaceuticals Ltd.). Total holding count decreased from 42 to 41 stocks.